Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 17;11:10431. doi: 10.1038/s41598-021-89770-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Study Design and Methods. This is a prospective non-interventional observational study carried out between March, 2017 and July, 2017 in Vitória, Espírito Santo, Brazil. A total of 140 patients with Autoimmune Disease patients (AID) including: Rheumatoid Arthritis (RA, n = 38), Spondyloarthritis (SpA, n = 51), Systemic Lupus Erythematosus (SLE, n = 21) and Sjögren’s Syndrome (SS, n = 30). A group Healthy Controls without diagnosis of autoimmune diseases (HC, n = 21) was also included. All participants received the primary dose of 17DD-YF vaccine (Bio-Manguinhos-FIOCRUZ) during the 2017 Brazilian YF vaccination campaign. Detailed inclusion and exclusion criteria are provided in Methods. Blood samples were collected from each participant at distinct time points, including: D0; Day3–4; Day5–6; Day7; Day14–D28. Serum samples were used for laboratorial analysis, including: YF-specific neutralizing antibodies analysis by Plaque Reduction Neutralizing Test (PRNT), YF viral RNAnemia (YF-Viremia) detection by quantitative real time PCR (qRT-PCR) and Serum Immunological Biomarkers quantification by Luminex Bio-plex assay.